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Context: Over the past several years, biomarkers have emerged as a 
diagnostic and therapeutic tool for cancer therapy. CD73 (ecto-5'-nucleotidase) 
which is a cell surface ectonucleotidase, mediates the conversion of 
extracellular Adenosine monophosphate (AMP) into adenosine through the 
purinergic signaling pathway. In this study the role of CD73 in different 
human cancers was investigated.  
Evidence Acquisition: The present study reviewed the articles related to the 
importance of CD73 as a therapeutic tool in human cancers which were 
published from 1990 to 2019. The publications were found by searching the 
valid databases for instance PubMed, Google Scholar, ProQuest, Scopus and 
Science Direct using keywords CD73, ectonucleotidase, therapy, cancer, etc. 
During the review process 90 articles were selected. 
Results: Different studies about the effect of CD73 on human malignancies 
show that CD73 is overexpressed in various types of cancer. Recent findings 
demonstrate that the extracellular adenosine can promote tumor growth and 
invasion. The significant regulatory role of CD73 has made it a suitable 
biomarker for cancer treatment.  
Conclusion: This study outlines the impact of CD73 on tumor growth, 
metastasis and angiogenesis. The findings are promising and can highlight the 
efficacy of this protein as a therapeutic tool in the context of anti-CD73 cancer 
therapy. 
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1. Context 
     It has been observed that a series of 
events such as the rapid proliferation of 
abnormal cells, immune escape, 
angiogenesis, inhibition of apoptosis, 
invasion and metastasis can lead to tumor 
malignancy [1, 2]. 
Over the past few years, the considerable 
progress in cancer immunotherapy has 
boosted   our      knowledge     about   tumor  
 
biology. Previous investigations have 
confirmed the efficacy of CD73 as a 
promising target for cancer therapy [3]. 
CD73 is encoded by NT5E gene, which is 
linked to the cell surface via a glycolipid 
molecule named 
glycosylphosphatidylinositol (GPI) and 
carries out essential roles in tumor 
processes. CD73 is one of the vital enzymes 
for adenosine production [4]. 
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Purinergic signaling represents a pathway in 
which purine nucleotides including 
Adenosine triphosphate (ATP) and  
Adenosine diphosphate (ADP) and 
nucleosides like adenosine are the 
fundamental elements [5]. In this pathway, 
P2 receptors can become active and 
metabolize the conversion of nucleotide to 
adenosine through releasing ATP/ADP. 
Afterwards, these nucleosides might bind to 
one other and initiate events that cause 
progression of tumor processes [6, 7]. 
Furthermore, CD73 is also a cell adhesion 
molecule (CAM) which mediates 
lymphocyte adhesion to endothelium and 
adjusts the interplay of cells with 
extracellular matrix ingredients to intervene 
in cancer invasive attributes [8-10]. 
Generally, the dual functions of CD73 
including enzymatic and non-enzymatic 
roles are contributed to tumor malignancies 
[11].  
CD73 has been discovered to be 
overexpressed in a multitude of diverse 
types of cancers including breast cancer, 
leukemia and melanoma [11-13]. 
Considering such a key role, CD73 has 
become an appropriate target for research 
with potential applications in cancer 
treatment [14]. The aim of this study was to 
investigate the significant roles of CD73 in 
promoting tumor growth, metastasis and 
angiogenesis which could explain the 
importance of this appealing biomarker in 
order to cure the malignancies in the future. 
 
2. Evidence Acquisition 
     In this study a search for articles that 
were related to the value of CD73 molecule 
in order to treatment human malignancies 
was performed in Pub Med, Google 
Scholar, ProQuest, Scopus and Science 
Direct databases. The search keywords 
including but not limited to, CD73, 
ectonucleotidase, therapy and cancer. 210 
articles were collected, the retrieved 
publications were published from 1990 to 
2019. The title and abstract of the acquired 
articles were checked and irrelevant papers 
and those which were not in English or their 
full text were not attainable excluded from 
the review. Afterwards the content of the 
publications was investigated and 90 
articles were included for the present 
review.   
3. Results 
     The acquired results from the 
investigated articles considering the aim of 
the study are presented into six categories. 
1. Molecular Biology and Function of CD73 
2. Expression of CD73 in Cancer Cells 
3. The Effect of CD73 on Tumor Growth  
4. The Effect of CD73 on Metastasis 
5. The Effect of CD73 on Angiogenesis 
6. Targeting CD73 for Cancer Treatment 
 
3.1 Molecular Biology and Function of 
CD73 
     NT5E gene is located on chromosome 6 
and is translated into CD73 which is a GPI 
anchored nucleotidase [15]. Studies on the 
structure of this enzyme has demonstrated 
that it has three domains, including the C-
terminal which contains the substrate 
binding site and fragments that play a role 
in dimerization, the N-terminal consisting 
of two metal ion binding sites and finally, 
the joint region that allows the vast 
movement of this protein by connecting the 
N and C- terminal domains (Figure 1). 
Substitution of a specific part of the C-
terminal for GPI anchor allows CD73 to 
bind to the cell surface [16, 17].  
CD73 along with CD39 can play a vital role 
in the purinergic signaling pathway in order 
to catalyze the hydrolysis of ATP to 
adenosine (Figure 2).  
ATP and ADP are dephosphorylated into 
AMP via CD39. Afterwards, CD73 
catabolizes the conversion of AMP into 
adenosine [18-20]. Recently, the significant 
effect of adenosine on immune escape and 
tumor proliferation has been observed [21]. 
CD73 is found in many cells including 
endothelial cells, epithelial cells and 
lymphocytes; this protein has many 
functions in inflammation, hypoxia, 
ischemia, etc [22-24].
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Figure 1. CD73 consists of three domains, including the N- terminal that contains two metal ion binding sites, the C -
terminal which has a substrate binding site, and a α- helix that forms a flexible joint region. CD73 is connected to the cell 
membrane via a GPI- anchor 
 
 
3.2 Expression of CD73 in Cancer 
Cells 
     CD73 is highly expressed in a broad 
spectrum of cancer cells. A number of 
studies demonstrated the elevated levels of 
CD73 are associated with invasion and 
metastatic properties in cancer cells [25]. 
In the context of brain carcinoma, the role 
of CD73 is impressive. CD73 is upregulated 
in glioblastoma multiforme (GBM) cells 
[26, 27]. CD73 and adenosine cooperate 
with each other to enhance invasion and 
drug resistance in glioblastoma malignant 
cells [28]. CD73 also traced on glioma cells 
[26, 29]. 
Studies on triple-negative breast cancer 
(TNBC) indicate that overexpression of 
CD73 can lead to poor prognosis and 
inhibition of CD73 probably can be 
effective for treatment of these cells [30-
33]. Another  study shows that estrogen 
receptor signaling has a converse relation 
with CD73 expression in breast carcinoma 
cells [12]. Further studies on TNBC show 
that blocking of CD73 can decrease the 
formation of endothelial vessels in 4T1 
murine cell lines [34]. The blocking of ER 
with tamoxifen as an estrogen receptor 
modulator stimulates CD73 expression in 
ER+ cells whereas in ER- cells, it decreases 
the expression of CD73 [31].  
Colorectal carcinoma is considered to be a 
prevalent malignancy worldwide. Two 
comprehensive cohort studies indicate that 
upregulation of CD73 in colorectal cancer 
(CRC) patients is associated with low 
survival rate [35]. 
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Figure 2. CD73 in tandem with CD39 generates extracellular adenosine (Ado). CD39 mediates the conversion of ATP 
into AMP, CD73 which is an ectonucleotidase catalyzes the hydrolysis of AMP to adenosine 
 
In another study on CRC cells, 
overexpression of MIR30A led to the 
reduction of CD73 expression which 
inhibited the growth and apoptosis in 
mentioned cells [36]. 
Gastric carcinoma is the fourth most 
common cancer all over the world [37]. 
Hypoxia-inducible factor-1α (HIF-1α) is 
widely expressed on several types of 
carcinomas. There exists a relationship 
between CD73 and this factor in gastric 
cancer cells. Then, these two molecules 
might be the valuable prognostic indicators 
for this carcinoma [38].  
Ovarian cancer is one of the primary causes 
of cancer mortality among women [39]. 
High-grade serous (HGS) ovarian cancer is 
the most dangerous type of this cancer. It 
has been found that high level of CD73 is 
correlated with less chance of survival in a 
large number of cases [40]. CD73 has been 
a desirable target for ovarian cancer therapy 
in some preclinical studies [41, 42]. 
In prostate cancer which is the second most 
frequent neoplasia in men, CD73 expression 
intensity is connected with biochemical 
recurrence-free survival [43, 44]. These 
findings comply with another research that 
shows a clear correlation between over-
expression of CD73 and elevating the 
likelihood of lymph node metastasis in 
prostate cancer [45].  
The significant regulatory role of CD73 is 
observed in many other cancerous cells 
including bladder cancer, leukemia, 
glioblastoma, long cancer, etc [28, 46-48].  
 
3.3 The Effect of CD73 on Tumor 
Growth 
     Over the past several years, different 
kinds of research have revealed that 
overexpression of CD73 elevates the growth 
of cancerous cells.  
CD73 has an important role in immune 
escape, growth boosting and proliferation of 
neoplastic cells [49, 50]. In a study in 2010, 
knockdown of CD73 using shRNA 
inhibited the growth of breast carcinoma 
cells through affecting the cell apoptosis 
[51]. Additionally, suppressing CD73 in 
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4T1.2 mouse cells reduced tumor growth. 
Knocking down of transforming growth 
factor beta (TGF-β) signaling could 
indirectly decline the level of CD73 in 
myeloid cells and consequently, the tube 
formation and tumor proliferation were 
diminished [52]. 
Later, some studies showed that CD73 
could adjust the expression and 
phosphorylation of epidermal growth factor 
receptor (EGFR). EGFR is a leading factor 
in cell growth and ecto-5'-nucleotidase 
expression is significantly correlated with 
EGFR expression. Overexpression of CD73 
induces the EGFR expression which can 
lead to the growth of breast cancer cells 
[53]. Wang et al. found that downregulation 
of CD73 elevates penetration of CD8+ T 
cells into the tumor tissue and inhibits 
tumor proliferation in mice [41]. In a 
clinical research on nude mice which was 
transfected by breast cancer cells and CD73, 
the rate of hypodermal tumor proliferation 
was more accelerated in models that were 
CD73 positive than negative ones. In 
addition, CD73 suppression by siRNA 
could reduce tumor progression in 
xenotransplant mice [9, 51]. Stagg et al. 
reported that the expression of CD73 could 
remarkably confine CD8 positive T-cell–
mediated antitumor immunity in 
hematopoietic and non-hematopoietic cells. 
Most importantly, they represented that 
overexpression of CD73 on regulatory T 
cells (Tregs) had a significant impact on the 
development of colon cancer [54]. 
Furthermore, the non-enzymatic activity of 
CD73 also had promotive effects on tumor 
proliferation [55, 56]. 
 
3.4 The Effect of CD73 on Metastasis 
     Tumor metastasis is the most invasive 
and deadly feature of malignancies [57]. 
Therefore, understanding metastasis 
associated pathways seems to be of great 
importance. Different findings display that 
CD73 could enhance the tumor metastasis 
[58, 59]. 
Many studies have demonstrated that the 
generation of adenosine by CD73 activity 
mediates the spread of cancer cells [60, 61]. 
CD73 upregulates in lymphoid metastasis 
breast carcinoma cells in comparison with 
non-metastasizing cells which indicates the 
effect of this molecule in progression of 
metastasis [62]. CD73-generated adenosine 
increases metastasis using the A2B 
adenosine receptor [30].  
High expression of CD73 on abnormal cells 
is related to metastasis of breast, cervical 
and ovarian cancer [63-65]. 
CD73 can induce aggressive features and 
activate epithelial-mesenchymal transition 
(EMT) in some cancer cells through its non-
enzymatic function [66]. Zhi et al. found 
that the suppression of EGFR in CD73 
transfected breast carcinoma cells can 
control the aggressive properties of the 
mentioned cells [53]. 
 
3.5 The Effect of CD73 on 
Angiogenesis 
     Angiogenesis is an essential process for 
distant invasion of tumor cells. Cancer cells 
are able to infiltrate into immature vessels 
in order to transfer into other organs [67]. 
Many investigations have proved the role of 
CD73 in tumor angiogenesis [68, 69].  
Studies on mouse melanoma cells showed 
that CD73 takes part in the development of 
new blood vessels and suppression of CD73 
diminishes the angiogenesis in these cells 
[68]. In a research on pulmonary 
microvascular endothelial cells (PMECs), 
researchers demonstrated that development 
of structures which was similar to 
microvessels in CD73 negative cells was 
less than CD73 positive cells. The 
enzymatic and non-enzymatic activities of 
CD73 increased the invasion of capillary 
endothelial cells and angiogenesis. CD73 
overexpression can upregulate cyclin D1 
that is a checkpoint protein and lead to 
tumor growth and angiogenesis in PMECs. 
Moreover, CD73-generated adenosine can 
elevate the level of an angiogenic protein 
called vascular endothelial growth factor 
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(VEGF) and consequently, enhances 
angiogenesis [69]. Researchers also showed 
that inhibition of NT5E gene can reduce the 
blood vessel development in human 
umbilical vein endothelial cells (HUVEC) 
[34]. 
 
3.6 Targeting CD73 for Cancer 
Treatment 
     Cancer is a significant public health 
issue worldwide, accordingly finding the 
most effective therapeutic methods seems 
undeniably crucial [70]. Targeted therapy 
and immunotherapies possess advantages in 
comparison with conventional cytotoxic 
cancer treatments [14].  
Over the past years, investigation of CD73 
in many disorders demonstrated the clinical 
significance of this protein. Findings imply 
that CD73 overexpression leads to the drug 
and chemotherapy resistance in some tumor 
cells [71, 72]. With regard to targeted 
therapy, it can be pointed out that the 
treatment efficacy of CD73 as an appealing 
therapeutic biomarker is quite noteworthy 
[25, 34, 73].  
Targeting cancer biomarkers by monoclonal 
antibodies (mAbs) in the process of 
development [74]. Some of these mAbs 
have entered clinical trials; since 2017, 
many patients had been treated with anti-
CD73 mAb named BMS-986179 [75, 76]. 
In one study, anti-CD73 mAb therapy could 
postpone the tumor growth in some mice. 
The progression of lung metastases was also 
inhibited in these mice [30].  
𝛼, 𝛽-methylene adenosine-5'-disphosphate 
(APCP) is approximately a structural analog 
of ADP molecule which can suppress CD73 
enzymatic functions [51, 77]. The efficacy 
of APCP has been proved in various murine 
models including ovarian and lung tumors 
[41, 42, 54]. 
Additionally, using small interfering RNA 
(siRNA) can be effective for down-
regulation of CD73 on cancer cells which 
leads to tumor free survival in mice [42]. 
Ghalamfarsa et al. points that knockdown of 
CD73 with siRNA can control tumor 
growth in 4T1 cells and be associated with 
suppression of angiogenesis-inducer factors 
such as (VEGF)-A and VEGF-R2 [78].  
Using checkpoint inhibitors including anti-
PD-1, anti-PD-L1, anti-CTLA4 is a growing 
approach in cancer treatment. Adenosine 
can increase PD-1 expression in some T 
lymphocytes such as CD8 positive cells 
[79]. In fact, inhibition of adenosine A2A 
receptors and PD-1 can lead to promoting 
the antitumor function of these lymphocytes 




     CD73 through its enzymatic and non-
enzymatic activities plays a crucial role in 
the progression of cancer processes. A 
considerable body of evidence implies that 
CD73 is overexpressed in a broad spectrum 
of cancer cells. It is now obvious that CD73 
has an impressive effect in immune 
suppression, metastasis, tumor growth and 
angiogenesis. On the whole, findings 
propose CD73 could be an appropriate 
target for treatment of diverse cancers. 
Several clinical trials that targeted CD73 
therapy using mAbs anti-CD73 and small 
molecule inhibitors have presented eligible 
antitumor results in malignant murine cells. 
These outcomes could open the field for 
more research and offer a valuable 
anticancer tool which appears to be 
promising for translating anti-CD73 
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